β-地中海型贫血检测市场 - 全球产业规模、份额、趋势、机会、预测：按产品、技术、类型、最终用户、地区和竞争对手划分，2021-2031年

全球β-地中海贫血检测市场预计将从2025年的6.1495亿美元成长到2031年的10.5309亿美元，复合年增长率达到9.38%。

该市场依赖血液常规检查、血红蛋白电泳和分子遗传分析等诊断检测方法来检测由HBB基因突变引起的血红蛋白缺乏症。成长的主要驱动因素是全球遗传性血液疾病发生率的上升，以及高风险地区强制性婚前和产前筛检政策的实施。此外，旨在早期疾病管理以减轻终身输血带来的经济负担的公共卫生宣传活动，也持续加速了这些诊断解决方案的普及应用。

儘管有这些正面迹象，但在医疗资源匮乏、医疗资金不足的环境中，全面诊断的普及仍面临严峻挑战。基因检测的高昂自付费用阻碍了新兴经济体的普及，也成为疾病控制的一大障碍。国际地中海贫血联合会预测，到2024年，超过80%的中高发病率国家将缺乏国家层面协调和支持的预防项目，凸显了诊断需求与现有基础设施之间存在的巨大差距。

市场驱动因素

政府主导的新生儿和产前筛检计画的扩展是全球β-地中海贫血检测市场的主要驱动力，尤其是在亚洲和地中海等高发生地区。各国政府正加速推动大规模筛检项目，以便及早发现带因者，并减轻治疗输血依赖型患者所带来的长期经济负担。这项监管转变正在将以往分散的检测模式转变为一项系统的公共卫生优先事项，从而显着增加年度诊断检测量。例如，印度卫生和家庭福利部报告称，截至2025年3月，全国筛检计画已成功筛检了1,587,903名地中海筛检患者，显示政府主导的干预规模庞大。

同时，分子诊断技术的进步和基因疗法的商业化正在重塑市场格局，对精准的基因分型至关重要。基因编辑疗法的核准和应用需要严格的分子检测来验证患者合格并追踪治疗效果，从而推动了对高度复杂基因检测的需求。根据Vertex Pharmaceuticals于2025年8月发布的2025年第二季财报，自Casgevy基因疗法问世以来，全球已有约115名患者开始进行细胞采集，这直接刺激了伴随诊断通讯协定市场的发展。然而，差距依然存在。正如国际地中海贫血联合会在2025年3月指出的那样，中低收入国家超过75%的患者面临血液短缺，这凸显了建立便捷的诊断基础设施以提升传统和先进治疗水平的迫切需求。

市场挑战

阻碍全球β-地中海贫血检测市场扩张的主要障碍是资源匮乏地区经济准入的严重不足，这源自于医疗资金不足和高昂的自付费用。在许多新兴经济体，基因检测的高昂费用是进入该市场的主要障碍。当家庭被迫承担全部医疗费用时，他们必须优先考虑维持生存所需的紧急治疗，而非预防性诊断，这反过来又抑制了高发地区对筛检检测的需求。这种经济限制缩小了诊断试剂生产商能够有效参与的市场规模，因为进入医疗基础设施不足以支持这些关键检测的地区十分困难。

为了佐证这种经济压力，国际地中海贫血联合会2024年的报告指出，在90%以上地中海贫血中高发国家，患者仍需要自费支付医疗费用。这种对个人资金的严重依赖与低检测率直接相关，因为对于很大一部分高风险族群而言，由于无力支付后续治疗费用，初次诊断本身就造成了经济负担。

市场趋势

在分散式环境中，即时诊断（POC）设备的兴起正在从根本上改变β-地中海贫血检测的可及性，尤其是在缺乏集中式实验室的地区。这一趋势标誌着检测方式从依赖复杂的高效液相层析（HPLC）系统转向使用携带式电池驱动装置，这些设备能够在当地诊所提供明确的诊断结果。这些设备能够实现现场筛检和诊断，解决了重大的物流难题，并大幅降低了因需要长途跋涉进行追踪预约而导致的患者流失率。这种发展趋势正在推动对行动解决方案的生产和分销管道进行大量投资。例如，2025年9月，MedAccess宣布与Hemex Health建立策略合作伙伴关係，提供250万美元的营运资金框架，以扩大该公司「Gazelle」诊断平台的覆盖范围。 Gazelle是首款能够在资源匮乏的市场中定量检测β-地中海贫血血红蛋白变异体的携带式设备。

同时，次世代定序（NGS）技术的引入，为精准诊断建立了新的标准，用于检测那些常被传统方法忽略的罕见复杂突变。随着临床管理向个体化方向发展，实验室正从传统的电泳方法转向高通量定序平台，以识别非缺失突变和影响疾病严重程度的修饰因子。这种技术变革对于预防严重出生缺陷至关重要，因为它可以在遗传多样性受限的人群中进行更精准的带因者筛检。为了验证这种准确性的提升，华大基因于2025年5月在《遗传学与基因组筛检杂誌》（Journal of Genetics and Genomics）上发表的一项研究表明，对28,043名育龄妇女进行高通量定序，能够准确识别罕见的血红蛋白变异，其检出率优于传统的血液学筛检方法。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球β-地中海贫血检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（套装、耗材）
  • 透过技术手段（产前诊断、全血球计数、DNA检测等）
  • 依类型（重地中海型贫血、中间型地中海型贫血）
  • 依最终使用者（医院、专科诊所、诊断中心等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美β-地中海贫血检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲β-地中海型贫血检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区β-地中海贫血检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲β-地中海贫血检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲β-地中海贫血检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球β-地中海贫血检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• MedGenome
• 3B BlackBio Biotech India Limited
• Bio-Rad Laboratories Inc.
• ViennaLab Diagnostics
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioMedomics Inc.
• Asper Biogene
• Tosoh Bioscience Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Beta Thalassemia Testing Market is projected to expand from USD 614.95 Million in 2025 to USD 1053.09 Million by 2031, achieving a CAGR of 9.38%. This market relies on diagnostic assays, including Complete Blood Count, hemoglobin electrophoresis, and molecular genetic analysis, to detect hemoglobin deficiencies resulting from HBB gene mutations. Growth is chiefly propelled by the rising global incidence of hereditary blood disorders alongside the implementation of mandatory premarital and prenatal screening policies in high-risk areas. Furthermore, public health campaigns aimed at early disease management to alleviate the financial strain of lifelong transfusion therapies continue to encourage the uptake of these diagnostic solutions.

Despite these positive indicators, the market confronts substantial hurdles regarding the availability of comprehensive diagnostics in resource-constrained environments lacking adequate healthcare funding. The significant out-of-pocket expenses required for genetic verification frequently discourage widespread utilization in emerging economies, establishing a formidable barrier to disease control. According to the Thalassaemia International Federation, in 2024, nationally coordinated and supported prevention programmes were nonexistent in over 80% of countries with medium to high disease prevalence, highlighting the severe gap between diagnostic necessities and the existing infrastructure.

Market Driver

The broadening of government-enforced newborn and prenatal screening initiatives serves as the principal engine driving the Global Beta Thalassemia Testing Market, especially within high-prevalence zones in Asia and the Mediterranean. Governments are increasingly establishing large-scale screening programs to detect carriers early and reduce the long-term financial burden associated with treating transfusion-dependent patients. This regulatory momentum is transforming a previously disjointed testing environment into a structured public health priority, thereby substantially increasing the annual volume of diagnostic assays. For example, according to the Ministry of Health and Family Welfare (India), in April 2025, the national screening initiative reported successfully screening 1,587,903 individuals for thalassemia as of March 2025, illustrating the immense scope of these government-led interventions.

Concurrently, technological progress in molecular diagnostics and the commercialization of gene therapies are redefining the market landscape by demanding precise genetic characterization. The authorization and deployment of gene-editing treatments necessitate stringent molecular testing to verify patient eligibility and track treatment success, consequently fueling the demand for high-complexity genetic tests. According to Vertex Pharmaceuticals' 'Second Quarter 2025 Financial Results' in August 2025, roughly 115 patients worldwide had commenced cell collection for the Casgevy gene therapy since its introduction, directly invigorating the market for companion diagnostic protocols. Nevertheless, inequalities persist; as noted by the Thalassaemia International Federation in March 2025, blood insufficiency remains a reality for more than 75% of patients in low- and middle-income countries, emphasizing the critical requirement for accessible diagnostic infrastructure to bolster both traditional and advanced therapeutic care.

Market Challenge

The major obstacle hindering the expansion of the Global Beta Thalassemia Testing Market is the acute lack of financial accessibility in resource-poor regions, stemming from inadequate healthcare funding and prohibitive out-of-pocket costs. In numerous emerging economies, the substantial expense linked to genetic verification creates a significant entry barrier. When families are compelled to shoulder the entire financial weight of healthcare, they often bypass preventative diagnostics to address immediate survival necessities, thereby dampening the demand for screening assays in areas with the highest genetic prevalence. This economic restriction effectively curtails the addressable market size, as diagnostic manufacturers find it difficult to enter territories where the healthcare infrastructure does not subsidize these vital tests.

Confirming this financial pressure, the Thalassaemia International Federation reported in 2024 that patients in over 90% of countries with medium to high disease prevalence remained reliant on out-of-pocket payments for their care. This strong dependence on personal funding is directly linked to reduced testing adoption rates, as the inability to pay for subsequent treatment makes the initial diagnosis financially unfeasible for a large portion of the at-risk population.

Market Trends

The rise of Point-of-Care (POC) diagnostic devices in decentralized environments is fundamentally transforming access to beta thalassemia testing, especially in areas devoid of centralized laboratory facilities. This trend marks a shift away from dependence on intricate High-Performance Liquid Chromatography (HPLC) systems toward portable, battery-powered units capable of providing definitive results in community clinics. These devices resolve critical logistical challenges by facilitating on-site screening and diagnosis, which drastically cuts patient drop-out rates caused by long travel distances for follow-up appointments. This evolution is drawing significant investment to expand manufacturing and distribution channels for these mobile solutions; for instance, MedAccess announced in September 2025 a strategic collaboration committing a $2.5 million working capital facility to Hemex Health to broaden access to its Gazelle diagnostic platform, the first portable device able to quantify hemoglobin variants for beta thalassemia in low-resource markets.

At the same time, the incorporation of Next-Generation Sequencing (NGS) for precision diagnosis is setting a new benchmark for detecting rare and complex mutations that conventional methods frequently overlook. As clinical management evolves toward personalization, laboratories are advancing beyond standard electrophoresis to high-throughput sequencing platforms capable of identifying non-deletional mutations and modifiers that influence disease severity. This technological shift is essential for averting severe birth defects through more exact carrier screening in diverse populations where genetic heterogeneity restricts the effectiveness of older screening instruments. Substantiating this enhanced precision, a study published in the 'Journal of Genetics and Genomics' by BGI Genomics in May 2025 revealed that applying high-throughput sequencing to 28,043 women of childbearing age facilitated the accurate identification of rare hemoglobin variants, proving a detection rate superior to that of traditional hematological screening methods.

Key Market Players

• MedGenome
• 3B BlackBio Biotech India Limited
• Bio-Rad Laboratories Inc.
• ViennaLab Diagnostics
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• BioMedomics Inc.
• Asper Biogene
• Tosoh Bioscience Inc

Report Scope

In this report, the Global Beta Thalassemia Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beta Thalassemia Testing Market, By Product

• Kits
• Consumables

Beta Thalassemia Testing Market, By Technology

• Prenatal Diagnosis
• Complete Blood Count
• DNA Testing
• Others

Beta Thalassemia Testing Market, By Type

• Thalassemia Major
• Thalassemia Intermedia

Beta Thalassemia Testing Market, By End-User

• Hospitals & Specialty Clinics
• Diagnostics Centers
• Others

Beta Thalassemia Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Beta Thalassemia Testing Market.

Available Customizations:

Global Beta Thalassemia Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Beta Thalassemia Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits, Consumables)
  • 5.2.2. By Technology (Prenatal Diagnosis, Complete Blood Count, DNA Testing, Others)
  • 5.2.3. By Type (Thalassemia Major, Thalassemia Intermedia)
  • 5.2.4. By End-User (Hospitals & Specialty Clinics, Diagnostics Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Beta Thalassemia Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Beta Thalassemia Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Beta Thalassemia Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Beta Thalassemia Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By End-User

7. Europe Beta Thalassemia Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Beta Thalassemia Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Beta Thalassemia Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Beta Thalassemia Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Beta Thalassemia Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Beta Thalassemia Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By End-User

8. Asia Pacific Beta Thalassemia Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Beta Thalassemia Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Beta Thalassemia Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Beta Thalassemia Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Beta Thalassemia Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Beta Thalassemia Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Beta Thalassemia Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Beta Thalassemia Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Beta Thalassemia Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Beta Thalassemia Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By End-User

10. South America Beta Thalassemia Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Beta Thalassemia Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Beta Thalassemia Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Beta Thalassemia Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Beta Thalassemia Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. MedGenome
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. 3B BlackBio Biotech India Limited
• 15.3. Bio-Rad Laboratories Inc.
• 15.4. ViennaLab Diagnostics
• 15.5. Thermo Fisher Scientific Inc.
• 15.6. PerkinElmer Inc.
• 15.7. BioMedomics Inc.
• 15.8. Asper Biogene
• 15.9. Tosoh Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer